Comparison 1. Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFrEF (long‐term treatment (≥ 6 months) with ivabradine).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1.1 Mortality from cardiovascular causes (follow‐up range 19 months to 23 months)	3	17676	Risk Ratio (M‐H, Random, 95% CI)	0.99 [0.88, 1.11]
1.2 Rate of serious adverse events	2	17399	Risk Ratio (M‐H, Random, 95% CI)	0.96 [0.92, 1.00]